profit from every $100 of sales.
$0$100
Revolution Medicines, Inc. Warrant
$8.15-5.78% today
+98.8% in 1 year
1-year low $1.881-year high $17.10
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Revolution Medicines, Inc. Warrant sold, what it kept, and what it did with the cash.
Sales went from $35.4 million in 2022 to $0 in 2025, with -$1.13 billion of profit last year.
SalesProfit
Revolution Medicines, Inc. Warrant vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Revolution Medicines, Inc. Warrant | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Revolution Medicines, Inc. Warrant's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 35 | 12 | 0 | 0 | |
| – | – | – | – | |
| -258 | -487 | -690 | -1,182 | |
| -249 | -431 | -589 | -1,091 | |
| -249 | -436 | -600 | -1,131 | |
| – | – | – | – | |
| – | – | – | – | |
| -730.0% | -4,207.1% | – | – | |
| -703.0% | -3,768.3% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 812 | 2,062 | 2,558 | 2,355 |
| Cash | 161 | 696 | 543 | 384 |
| Total debt | 64 | 88 | 136 | 159 |
| Total liabilities | 127 | 236 | 293 | 723 |
| 685 | 1,826 | 2,265 | 1,631 | |
| – | – | – | – | |
| -27.2% | -18.2% | -19.8% | -48.9% | |
| -36.3% | -23.9% | -26.5% | -69.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -224 | -351 | -557 | -898 | |
| 11 | 8 | 10 | 16 | |
| -235 | -358 | -568 | -914 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 31 | 62 | 79 | 118 |
Valuation
- –
- –
- 0.43
- 19.0×
- 0.0×
- –
- –
- -84.3%
- -4.8%
- 0.0%
Profitability
- 0.0%
- -4,207.1%
- -3,768.3%
- 0.0%
- -70.0%
- -34.4%
- -83.2%
- -60.9%
- -70.6%
- –
Growth
- −67.3%
- –
- −60.9%
- –
- +27.1%
Financial health
- -1.4×
- 0.10
- 6.9%
- -39.0×
- 6.80
- 6.80
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 952
Bottom 1%of 886
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -2.29 | -1.84 | −24.7% |
| Feb 25, 2026 | -1.86 | -1.58 | −17.6% |
News
Nvidia vs. Alphabet: The AI Revolution Is Big Enough for Both. Here's the Better Buy.Yahoo Finance · Nov 9, 2026Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?Yahoo Finance · Nov 8, 2026Google taught the world how to search. Now it faces a revolution it can’t afford to lose.MarketWatch · Oct 31, 2026Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?Yahoo Finance · Oct 27, 2026Nvidia vs. Micron: The AI Revolution Is Big Enough for Both. Here's the Better Buy.Yahoo Finance · Oct 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
39No pass
Philip Fisher
33No pass
Peter Lynch
12No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Revolution Medicines, Inc. Warrant
Is Revolution Medicines, Inc. Warrant a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Revolution Medicines, Inc. Warrant AI analysis
What does Revolution Medicines, Inc. Warrant do?
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. It is in Biotechnology.
Does Revolution Medicines, Inc. Warrant pay a dividend?
No. Revolution Medicines, Inc. Warrant does not pay a dividend at the moment.
How has Revolution Medicines, Inc. Warrant stock done over the past year?
Up 98.8% over the past twelve months, to $8.15. It traded between $1.88 and $17.10 and is 52.3% below its high.
Who are Revolution Medicines, Inc. Warrant's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Revolution Medicines, Inc. Warrant's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.